Biotech Values

[BTH]

I swear (and I am sure you will have many examples of how this does not happen all the time) but in a lot of these names that had HUGE runups in the stock PRIOR to getting approval and PRIOR to becoming a fundamental story there is just not much reason to own the stock any longer (after approval and marketing). The market has "pulled forward", 10s of years of revenues into the market-cap of names like DNDN and HGSI. HGSI is brutal, and the chart shows it. What was the revenue number on Benlysta last Q? $8 million?

I wouldn't be surprised to see HGSI close that gap from '09.